Ending the Epidemic Interventions in the Dental Setting - UH3
Launched by COLUMBIA UNIVERSITY · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Ending the Epidemic Interventions in the Dental Setting," is focused on improving how dental care teams can help prevent and manage HIV-1 infection using the latest technology. The goal is to make sure that best practices for HIV care are effectively delivered during dental visits, where many patients may not typically receive this kind of support.
While the trial is not yet recruiting participants, it is looking for members of the dental team—like dentists, hygienists, dental assistants, and care navigators—who have direct contact with patients. To participate, these individuals must be able to provide written consent. It’s important to note that anyone who cannot provide written consent will not be eligible for this study. Those involved can expect to learn how technology can enhance their ability to assist patients regarding HIV prevention and care during their dental appointments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Member of the Dental Team (Provider, Hygienist, Dental Assistant, Care Navigator) at one of the randomized sites with direct patient contact
- • Able to provide written informed consent.
- Exclusion Criteria:
- • - Inability to provide written informed consent.
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
Queens, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported